Khalid Alsulaiman Shared a New Study About Clinical Outcomes of Apixaban
Khalid Alsulaiman, Vice Chairman, Clinical Trial Management (CTM) at King Abdullah International Medical Research Center, shared a post on LinkedIn:
“Happy to share our new study titled: “*Evaluation of the Clinical Outcomes of Apixaban Use in Patients with Atrial Fibrillation and Uncontrolled Hypothyroidism: A Real-world Evidence*”, published in Clinical and Applied Thrombosis/Hemostasis.
In this study, we evaluated the effectiveness and safety of apixaban among patients with atrial fibrillation who also suffer from uncontrolled hypothyroidism. Our findings indicate that the use of apixaban in patients with AF and uncontrolled hypothyroidism was linked to higher rates of thrombosis and major bleeding compared to those without known hypothyroidism. These findings highlight the need for further research through larger prospective studies in this often-overlooked population.
We would like to thank all investigators who contributed to this project from the Saudi Critical Care Pharmacy Research (SCAPE) Platform, Saudi Society for Multidisciplinary Research Development and Education (SCAPE Society) and King Abdullah International Medical Research Center (كيمارك KAIMRC).”
Title: Evaluation of the Clinical Outcomes of Apixaban Use in Patients with Atrial Fibrillation and Uncontrolled Hypothyroidism: A Real-world Evidence
Authors: Khalid Al Sulaiman, Manal A Aljohani, Abdullah F Alharthi, Hisham A Badreldin, Mohammed Y Alzahrani, Rahaf A Alqahtani, Walaa A Alshahrani, Fatimah M Abudayah, Mohammad S Shawaqfeh, Ahmed A Alrashed, Alaa M Alenazi, Nouf S Alsagri, Mohammed Yahya Asiri, Zayed Asiri, Sulaiman Aljarallah, Yusuf M. Garwan, Lama S. Alfehaid, Abeer A. Alenazi, Tariq Aldebasi, Shmeylan Alharbi, Ahmed Aldemerdash, Amer Alzahrani, Ohoud Aljuhani

Read full article here.
Stay updated with Hemostasis Today.
-
Jan 6, 2026, 13:39JAMA Neurology: No Added Benefit of Dual Therapy After Ischemic Stroke in Case of AFib
-
Jan 6, 2026, 10:10This is Fantastic: Shirley D’Sa on Transfusion-Free Christmas Milestone for 𝛃-Thalassaemia Patient at UCLH
-
Jan 6, 2026, 09:53Hamideh Yadegari: Coagulation–Inflammation Crosstalk: Mechanisms, Pathways, and Clinical Implications
-
Jan 6, 2026, 09:52Antoine Francis: Plasma is Not Just Another Component of Healthcare…
-
Jan 6, 2026, 09:45Hurry to Join EHC Youth Leadership Workshop 2026
-
Jan 6, 2026, 09:41Andrew Petrosoniak Makes It to N1 on EMCases Best of 2025!
-
Jan 6, 2026, 09:35Sara Ng: Moving Beyond Management to Stewardship – “Advancing Anticoagulation Stewardship” Released by NQF
-
Jan 6, 2026, 09:30Wolfgang Miesbach: Excellent 4-Year Data of Etranacogene Dezaparvovec in Haemophilia B
-
Jan 6, 2026, 09:09Abdulrahman Nasiri: A New Perspective on Avatrombopag in Aplastic Anemia
